Visiongain states that the Global Hereditary Angioedema Market Set To Grow To $2.8bn By 2022

27 July 2018
Pharma

Visiongain’ has launched a new pharma report Global Hereditary Angioedema Market Forecast 2018-2028: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze. Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies
Hereditary Angioedema is a disorder characterized by reoccurring phenomena of severe swelling. Limbs, face airway and intestinal tract are the common areas of the body that swells up in this condition. This report evaluates the global market of hereditary angioedema in regions such as North America, Latin America, Europe, Asia-Pacific and the Middle East and Africa. Furthermore, this report provides detailed overview of various medical hereditary angioedema segments such as drug class, route of administration and distribution channel.
The lead analyst of the report commented “Hereditary angioedema (HAE) is a rare disease and the diagnosis of HAE is challenging in children. Lack of awareness, diagnostic testing limitations, and communication difficulties along with the differential diagnosis of the symptoms of this disorder contribute to this challenge. Delay in diagnosis leads to sub-optimal treatment of symptoms and reduced quality of life.”

Leading companies featured in the report include BioCryst Pharmaceuticals, Inc., CSL Limited, iBio, Inc., Ionis Pharmaceuticals, Inc., Pharming Group NV, Santarus, Inc., Shire PLC

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever